Takeda Pharmaceutical 過去の業績

過去基準チェック /36

Takeda Pharmaceuticalは、平均年間10.3%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間成長しています。収益は、平均年間1.2% 8.2%収益成長率で成長しています。 Takeda Pharmaceuticalの自己資本利益率は4.2%であり、純利益率は6.4%です。

主要情報

10.3%

収益成長率

10.0%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	8.2%
株主資本利益率	4.2%
ネット・マージン	6.4%
次回の業績アップデート	30 Jan 2025

Recent updates

収支内訳

Takeda Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:TKPH.F 収益、費用、利益 ( )JPY Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	4,546,083	289,996	1,091,066	725,957
30 Jun 24	4,413,134	149,920	1,075,736	734,339
31 Mar 24	4,263,762	144,067	1,053,819	728,617
31 Dec 23	4,169,049	178,219	1,023,306	695,012
30 Sep 23	4,154,414	191,626	1,018,085	682,260
30 Jun 23	4,113,631	301,398	1,013,867	652,459
31 Mar 23	4,027,478	317,017	997,234	633,325
31 Dec 22	3,944,611	274,525	965,908	616,009
30 Sep 22	3,749,354	213,167	934,687	569,758
30 Jun 22	3,591,868	197,389	897,964	547,214
31 Mar 22	3,569,006	230,059	886,327	526,087
31 Dec 21	3,465,991	438,515	897,171	495,680
30 Sep 21	3,401,450	473,105	888,737	484,868
30 Jun 21	3,345,565	431,178	892,983	471,424
31 Mar 21	3,197,812	376,005	875,514	455,765
31 Dec 20	3,199,240	180,631	895,464	486,660
30 Sep 20	3,221,804	56,051	921,830	491,903
30 Jun 20	3,243,917	119,743	928,229	486,343
31 Mar 20	3,291,188	44,241	964,268	492,088
31 Dec 19	3,236,697	13,275	965,530	485,736
30 Sep 19	2,876,782	83,262	867,314	440,388
30 Jun 19	2,496,511	63,959	790,113	407,257
31 Mar 19	2,097,224	135,192	692,728	368,257
31 Dec 18	1,780,976	110,414	608,443	317,675
30 Sep 18	1,769,726	140,738	616,726	321,777
30 Jun 18	1,772,125	120,339	622,667	321,719
31 Mar 18	1,770,531	186,886	628,106	325,441
31 Dec 17	1,785,773	190,172	632,833	324,485
30 Sep 17	1,762,667	163,457	622,191	314,755
30 Jun 17	1,746,286	160,202	616,779	310,763
31 Mar 17	1,732,051	114,940	615,867	311,625
31 Dec 16	1,729,967	132,194	614,187	312,149
30 Sep 16	1,754,130	150,081	627,784	332,841
30 Jun 16	1,795,088	155,110	633,600	337,807
31 Mar 16	1,807,378	80,166	650,336	335,704
31 Dec 15	1,831,096	-111,874	650,103	386,767
30 Sep 15	1,830,521	-152,827	642,957	386,950
30 Jun 15	1,812,971	-154,591	637,726	387,932
31 Mar 15	1,777,824	-145,775	612,489	367,741
31 Dec 14	1,744,795	75,405	474,242	356,593
30 Sep 14	1,714,694	103,390	497,474	342,907
30 Jun 14	1,692,531	110,981	522,831	339,169
31 Mar 14	1,691,685	106,658	556,210	341,560
31 Dec 13	1,655,033	103,330	1,036,831	10,620

質の高い収益: TKPH.Fには¥245.4B } という大きな一回限りの損失があり、過去 12 か月の財務実績が30th September, 2024に影響を及ぼしています。

利益率の向上: TKPH.Fの現在の純利益率 (6.4%)は、昨年(4.6%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: TKPH.Fの収益は過去 5 年間で年間10.3%増加しました。

成長の加速: TKPH.Fの過去 1 年間の収益成長率 ( 51.3% ) は、5 年間の平均 ( 年間10.3%を上回っています。

収益対業界: TKPH.Fの過去 1 年間の収益成長率 ( 51.3% ) Pharmaceuticals業界54.6%を上回りませんでした。

株主資本利益率

高いROE: TKPH.Fの自己資本利益率 ( 4.2% ) は低いとみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/17 04:24
終値	2024/12/17 00:00
収益	2024/09/30
年間収益	2024/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Takeda Pharmaceutical Company Limited 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。39

アナリスト	機関
Ishan Majumdar	Baptista Research
Atsushi Seki	Barclays
Koichi Mamegano	BofA Global Research

Takeda Pharmaceutical 過去の業績

過去 基準チェック /36

主要情報

最近の業績更新

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Recent updates

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)